Lupin Ltd has reported a strong start to the fiscal year, with net profit for Q1 FY2026 (April–June 2025) rising 51.5% year-on-year to ₹1,221.5 crore, compared to ₹805.5 crore in the same quarter last year.
The company's revenue from operations increased by 12% to ₹6,268.3 crore, up from ₹5,600.3 crore during Q1 FY2025.
Lupin’s EBITDA rose 38% to ₹1,806.3 crore, up from ₹1,308.8 crore in the year-ago period. The EBITDA margin expanded by 560 basis points to 29.3%, reflecting improved operational efficiencies. Research and development (R&D) spending stood at ₹484.4 crore, accounting for 7.9% of sales, compared to ₹350 crore (6.3% of sales) in Q1 of the previous fiscal.
Commenting on the results, Nilesh Gupta, Managing Director, Lupin, said:
"We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. Our sharpened focus on compliance, innovation, and technology positions us well to unlock sustainable growth."
United States:
US sales rose 24.3% to ₹2,404.1 crore ($282 million), from ₹1,933.7 crore ($231 million) in Q1 FY2025.
The US accounted for 39% of Lupin’s global sales.
The company launched 3 new products in the US during the quarter.
Lupin received 2 new ANDA approvals from the US FDA, bringing cumulative ANDA filings to 442, with 342 approvals as of June 30, 2025.
Lupin now has 49 First-to-File (FTF) opportunities, including 19 exclusive FTFs.
The company has filed 92 Drug Master Files (DMFs) in the US to date.
With 139 generic products on the US market, Lupin continues to rank as the third-largest pharmaceutical company by prescriptions in both the US generics and overall prescription markets.
India:
India sales grew by 7.8% year-on-year to ₹2,089.4 crore, from ₹1,938.1 crore in Q1 FY2025.
India accounted for 34% of Lupin’s global sales.
Formulations sales in India rose 8.6%, reflecting continued domestic demand and product performance.